Can patients safely take a break from blood cancer treatment?

This trial is testing whether patients with newly diagnosed multiple myeloma can safely take a break from their cancer medication after it has worked well, rather than continuing it indefinitely. The medication being tested is a three-drug combination called daratumumab-lenalidomide-dexamethasone. Researchers want to know if stopping treatment temporarily—and restarting only when needed—might reduce side effects and improve quality of life without compromising how long patients survive.

Currently, patients with multiple myeloma take this medication continuously until it stops working, but no one knows if this approach actually helps patients live longer. Continuous treatment can cause serious side effects, damage the body's ability to tolerate future therapies, and is very expensive. This trial exists to find out whether taking scheduled breaks from the medication might be just as effective while reducing harm and improving daily life.